Results 61 to 70 of about 16,485 (256)
COX‐2 in lung cancer: Mechanisms, development, and targeted therapies
Chronic Diseases and Translational Medicine, Volume 10, Issue 4, Page 281-292, December 2024.COX‐2 functions in the tumor microenvironment. Abstract Lung cancer (LC) is the leading cause of cancer‐related death worldwide, with non‐small cell lung cancer (NSCLC) comprising 85% of all cases. COX‐2, an enzyme induced significantly under stress conditions, catalyzes the conversion of free arachidonic acid into prostaglandins.
Xueqi Liu +4 more
wiley +1 more source
Specific immunotherapy in renal cancer: a systematic review
Therapeutic Advances in Urology, 2017 Background: Renal cell cancer (RCC) is the tenth most common malignancy in adults. In recent years, several approaches of active and passive immunotherapy have been studied extensively in clinical trials of patients with RCC.
Armin Hirbod-Mobarakeh +6 more
doaj +1 more source
Establishment of Mouse Lymphokine‐activated Killer Cell Clones and Their Properties [PDF]
Japanese Journal of Cancer Research, 1991 To assess the properties of lymphokine‐activated killer (LAK) cells, we established mouse LAK cell clones from LAK cell lines induced from C57BL/6 mouse spleen cells. Although these clones expressed similar phenotypes to the parent LAK cells, Lyt‐2 was expressed in a restricted portion of the clones.
Yoshiyuki Hashimoto +5 more
openaire +3 more sources
Journal of Clinical Laboratory Analysis, Volume 38, Issue 23, December 2024.Mycobacterium tuberculosis acts as the causative agent of human tuberculosis and is regarded as one of the most adaptable human pathogens. M. tuberculosis possesses several virulence factors that help the bacterium evade mucous barriers. The infection caused by M.
Noura Mohammadnabi +8 more
wiley +1 more source
Organ Medicine, Volume 1, Issue 2, Page 70-84, December 2024.This article comprehensively analyzes the pivotal role of ezrin, an ERM protein family member, in diverse tumor types, highlighting its immunomodulatory capabilities and associations with tumor progression, immune cell infiltration, and therapeutic responses.
Ruiqi Chen +6 more
wiley +1 more source
Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. [PDF]
, 1990 The majority of human NK cells express low affinity IgG Fc receptors (CD16+), whereas a minor subset of NK cells lack Fc receptor expression (CD16-). In contrast to CD16+ NK cells that express only p75 IL-2 receptors, CD16- NK cells constitutively co ...
Lanier, LL, Nagler, A, Phillips, JH
core
Dynamic changes in macrophage polarization during the resolution phase of periodontal disease
Immunity, Inflammation and Disease, Volume 12, Issue 10, October 2024.This is the first translational studies to longitudinally assess the M/M2 MΦ profiles before and after therapy in periodontitis subjects and can serve as the first step in examining current treatment strategies to include investigations on the role of macrophage immune mediated regulatory networks governing periodontal disease pathogenesis.
Juhi R. Uttamani +6 more
wiley +1 more source
Australasian Journal of Dermatology, Volume 65, Issue 6, Page 491-504, September 2024.Abstract Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions characterised by keratinocyte apoptosis, necroptosis and epidermal detachment. Several cytokines and cytotoxic proteins have been shown to be elevated in the blood and skin of SJS/TEN sufferers and biologics such as intravenous immune ...
Thomas Jonathan Stewart +2 more
wiley +1 more source
Structure and specificity of T cell receptor gamma/delta on major histocompatibility complex antigen-specific CD3+, CD4-, CD8- T lymphocytes. [PDF]
, 1988 Analyses of TCR-bearing murine and human T cells have defined a unique subpopulation of T cells that express the TCR-gamma/delta proteins. The specificity of TCR-gamma/delta T cells and their role in the immune response have not yet been elucidated. Here
Bluestone, JA +4 more
core
Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients [PDF]
, 1997 Cell lymphomas which often contain the Epstein-Barr virus (EBV) make up the preponderance of tumors that collectively have been termed posttransplant lymphoproliferative disorders (PTLD).
Alard +14 more
core +2 more sources